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Introduction
Cell-free hemoglobin (CFH) is released into the plasma in conditions associated with RBC hemolysis 
including malaria, sickle cell disease, thalassemia, transfusion of  stored RBCs, and extracorporeal circula-
tion. Recently, CFH elevations have also been documented during bacterial sepsis (1–5). These increased 
plasma CFH levels have correlated with increased morbidity and mortality in preclinical and clinical stud-
ies (3, 5–10). Previous reports show that the release of  CFH following stored-RBC transfusion is associated 
with increased mortality in canine models of  S. aureus pneumonia, causing septic shock (11). The patho-
physiology and mortality correlated with the presence and severity of  pneumonia and the levels of  both 
plasma CFH and plasma free iron. These findings were ameliorated during infection by washing the RBC 
concentrates to remove CFH and iron that accumulated during storage (12, 13).
The effects of  intravascular hemolysis are postulated to be mediated by both direct and indirect mech-
anisms. Direct injury may be related to extravascular nitric oxide (NO) scavenging and reactive species 
formation by CFH; subsequent vasoconstriction, causing ischemic endothelial damage (1, 2, 10, 14); or the 
release of  heme and iron producing oxidative tissue injury (15–20). Proposed indirect mechanisms include 
During the last half-century, numerous antiinflammatory agents were tested in dozens of clinical 
trials and have proven ineffective for treating septic shock. The observation in multiple studies 
that cell-free hemoglobin (CFH) levels are elevated during clinical sepsis and that the degree of 
increase correlates with higher mortality suggests an alternative approach. Human haptoglobin 
binds CFH with high affinity and, therefore, can potentially reduce iron availability and oxidative 
activity. CFH levels are elevated over approximately 24–48 hours in our antibiotic-treated canine 
model of S. aureus pneumonia that simulates the cardiovascular abnormalities of human septic 
shock. In this 96-hour model, resuscitative treatments, mechanical ventilation, sedation, and 
continuous care are translatable to management in human intensive care units. We found, in this S. 
aureus pneumonia model inducing septic shock, that commercial human haptoglobin concentrate 
infusions over 48-hours bind canine CFH, increase CFH clearance, and lower circulating iron. Over 
the 96-hour study, this treatment was associated with an improved metabolic profile (pH, lactate), 
less lung injury, reversal of shock, and increased survival. Haptoglobin binding compartmentalized 
CFH to the intravascular space. This observation, in combination with increasing CFHs clearance, 
reduced available iron as a potential source of bacterial nutrition while decreasing the ability for 
CFH and iron to cause extravascular oxidative tissue injury. In contrast, haptoglobin therapy had 
no measurable antiinflammatory effect on elevations in proinflammatory C-reactive protein and 
cytokine levels. Haptoglobin therapy enhances normal host defense mechanisms in contrast to 
previously studied antiinflammatory sepsis therapies, making it a biologically plausible novel 
approach to treat septic shock.
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heme-enhanced proinflammatory, innate immune responses damaging tissues (21, 22), and release of  free 
iron, which worsens established infection by providing an essential nutrient that augments bacterial growth 
(11, 23). Additional support for the iron hypothesis has been supplied by studies using commercial i.v. iron 
preparations in a canine bacterial pneumonia model (24).
The normal low levels of  CFH released during RBC turnover are rapidly cleared from the circu-
lation through binding to haptoglobin, a naturally occurring plasma protein that forms high-affinity, 
high-molecular weight (~150,000–400,000 Daltons) haptoglobin-hemoglobin complexes that are 
cleared by the reticuloendothelial system (16, 25). Clearance of  haptoglobin-hemoglobin complexes 
during mild hemolysis is an efficient process. However, during conditions associated with excessive 
hemolysis, haptoglobin clearance can be saturated, resulting in circulation of  CFH, heme, and iron 
(16, 17, 26). Large molecular weight haptoglobin-hemoglobin complexes can lead to rapid rises in 
intravascular levels and prolonged half-life of  bound hemoglobin. The complexing also binds the free 
iron and heme in CFH and prevents these toxic products from extravasating into the extravascular 
space and causing injury.
We hypothesized that administration of  pharmacologic doses of  haptoglobin might reduce morbidity 
and mortality in our canine model of  transfusion during sepsis. In a series of  studies using a commercially 
fractionated plasma-derived haptoglobin concentrate, we found that excess haptoglobin improves outcomes 
in both transfused and, unexpectedly, nontransfused septic animals. These findings suggest that administra-
tion of  haptoglobin may be an effective clinical therapy for managing sepsis and septic shock.
Results
Mortality. Animals with S. aureus pneumonia that were exchange-transfused and randomized to receive 
haptoglobin (n = 9) had a significantly decreased mortality rate compared with animals receiving no hap-
toglobin (septic controls receiving PBS, n = 9) (44% vs. 78% [43% relative decrease]; P = 0.03 stratified log-
rank test) (Figure 1A). Animals with S. aureus pneumonia that were not exchange-transfused and random-
ized to receive haptoglobin (n = 12) vs. no haptoglobin (septic controls receiving 25% albumin, n = 12) had 
a decreased mortality rate that approached statistical significance (50% vs. 75% [33% relative decrease]; P = 
0.16 stratified log-rank test) (Figure 1B). Haptoglobin infusion during sepsis was associated with a similar 
beneficial effect with or without exchange-transfusion (43% vs. 33% relative decrease in mortality; P = 0.36, 
for interaction, stratified Cox proportional hazards model).
Shock score. All animals were treated with vasopressors to normalize blood pressure. The shock score 
incorporates the amount of  vasopressor support (norepinephrine) required to normalize the mean arte-
rial pressure (13). Progressively positive and negative scores reflect more hypertension and hypotension, 
respectively. Overall, during S. aureus pneumonia, animals randomized to receive haptoglobin therapy had 
improved mean shock scores (more positive scores) compared with septic controls. In particular, for the 
septic animals undergoing RBC exchange transfusion, the beneficial effect of  haptoglobin therapy with 
improved shock scores became statistically significant at 36, 48, and 72 hours, and for the septic animals 
without RBC exchange-transfusions, the effect was statistically significant at 36, 48, and 60 hours (Figure 
1, C and D, respectively; Supplemental Figure 1; supplemental material available online with this article; 
https://doi.org/10.1172/jci.insight.123013DS1.
Lung injury score. The lung injury score (LIS) incorporates 5 variables of  lung function (mean pulmo-
nary artery pressure, alveolar arterial oxygen gradient, plateau pressure measurement, SpO2, and respira-
tory rate) to detect lung injury (13). Overall, during S. aureus pneumonia, animals randomized to receive 
haptoglobin infusion had improved mean LIS scores (lower scores indicating less lung injury) compared 
with septic controls. In particular, for the septic animals undergoing RBC exchange-transfusion, the bene-
ficial effect of  haptoglobin therapy became statistically significant at 36, 48, and 60 hours, while — for the 
septic animals that were not exchange-transfused — statistical significance was noted at 10, 24, 36, 48, 60, 
and 72 hours (Figure 1, E and F, and Supplemental Figure 2).
CFH. During sepsis with RBC exchange transfusion, mean plasma CFH levels were significantly ele-
vated from baseline (0 hours) in animals randomized to receive haptoglobin therapy at 13, 24, 36, and 48 
hours and in septic controls (no haptoglobin) at 60 hours (Figure 2A). Mean combined bound hemoglo-
bin-haptoglobin and CFH levels at 60 hours were significantly lower in septic-transfused animals receiving 
haptoglobin (P = 0.02) and were similar to baseline values (P = 0.84), whereas septic-transfused controls 
still had significantly elevated mean CFH-alone levels at 60 hours compared with baseline.
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During sepsis without exchange transfusion, mean plasma CFH levels were significantly elevated at 16 
hours (P = 0.004) in animals receiving haptoglobin compared with baseline and were not significantly elevated 
at all other time points (Figure 2B). In septic controls without haptoglobin or exchange transfusion, CFH levels 
became elevated later, at 24 hours (P =  0.0002), and were not significantly elevated at all other time points 
(Figure 2B). Mean CFH levels at 24 hours were significantly lower in septic animals that were not exchange 
transfused receiving haptoglobin therapy (P = 0.01) and were similar to baseline values (P = 0.94), whereas 
septic controls still had significantly elevated CFH levels at 24 hours compared with baseline (P = 0.0002).
The CFH kinetics appear similar during sepsis with or without exchange transfusion, although — as 
expected — absolute levels are higher with RBC exchange. Specifically, haptoglobin therapy resulted in 
mean CFH increases earlier and more rapid clearance in both the exchange and no-exchange sepsis studies.
Nontransferrin bound iron (NTBI) levels. In animals with S. aureus pneumonia randomized to receive hap-
toglobin therapy and an exchange transfusion of  RBCs, there were no significant increases in mean NTBI 
Figure 1. Kaplan-Meier survival curve for the 96-hour sepsis study. The survival comparison in canines receiving haptoglobin or no haptoglobin with (A) 
or without (B) RBC exchange transfusion after S. aureus challenge. P values are denoted by asterisks indicating significance in comparison between each 
panel group using stratified log rank tests. (C and D) Mean shock scores (± SEM) at serial time points. The shock score accounts for the level of vasopressor 
support (norepinephrine) needed to maintain the mean arterial pressure at a preset normal level for canines (mean 80 mmHg). Shock score is compared over 
96 hours in canines receiving haptoglobin or no haptoglobin with (C) or without (D) RBC exchange transfusion. Changes from baseline are shown for each 
study group plotted from a common origin the mean value for animals at baseline. P values indicate significance in each group comparison in each panel 
and are denoted by asterisks (for changes over time) or crosses (comparing haptoglobin vs. no haptoglobin at each time point). (E and F) Mean (± SEM) lung 
injury scores (LIS) at serial time points. The LIS detects pulmonary damage via measurements in mean pulmonary artery pressure, alveolar-arterial oxygen 
gradient, plateau pressure, oxygen saturation, and respiratory rate. The LIS is plotted over time (x axis) for animals receiving haptoglobin or no haptoglobin 
with (E) or without (F) RBC exchange transfusion. Changes from baseline are shown for each study group plotted from a common origin, with the mean 
value for animals at baseline. P values indicate significance in each group comparison in each panel and are denoted by asterisks (for changes over time) or 
crosses (comparing haptoglobin vs. no haptoglobin at each time point). Comparisons of all variables (except survival) were made based on contrasts in linear 
mixed models, which allow us to account for repeated measurements of each animal and the actual pairing of animals within each cycle.
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Figure 2. Mean cell-free hemoglobin, nontransferrin bound iron, and haptoglobin cell–free hemoglobin binding at serial time points. The format is similar 
to Figure 1, except that cell-free hemoglobin (A and B) and nontransferrin bound iron (C and D) are shown. In addition, in panel E, haptoglobin cell–free 
hemoglobin binding is shown. (A and B) The Drabkin’s assay was used to measures both unbound and bound (with haptoglobin) cell-free hemoglobin. (E) 
Absorbance profile for mixtures of haptoglobin and hemoglobin. The samples were spun at 163,000 g at 25.2°C, and absorbance was measured as a function 
of time and sedimentation distance. Absorbance was normalized to the maximum absorbance of all samples. The sample with a molar ratio of 68 to 1 of 
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levels at all time points studied — 10, 13, 16, 24, and 48 hours — compared with baseline (time 0), and the 
mean NTBI levels at all these time points were in the normal range (<0.2 μM) (Figure 2C). Septic controls 
with exchange transfusion (no haptoglobin) also had no significant increases in mean NTBI compared with 
baseline levels at 10, 13, 16, 24, and 48 hours; however, in septic controls (no haptoglobin), the mean levels 
of  NTBI by 48 hours increased compared with baseline were trending to be elevated (P = 0.10) and reached 
the abnormal range (>0.2 μM) (Figure 2C).
In animals with S. aureus pneumonia and that were not exchange-transfusion randomized to receive 
haptoglobin therapy, there were no significant increases in mean NTBI levels at all time points studied — 
10, 13, 16, 24, and 48 hours — compared with baseline. In contrast, in septic controls (no haptoglobin), 
there were significant increases in mean NTBI levels compared with baseline at 24 hours (P = 0.001), with 
levels elevated and reaching the abnormal range (>0.20 μM) at 16 hours (P = 0.060) and 48 hours (P = 
0.056). At 24 hours, mean NTBI levels in septic animals that were not exchange-transfused were signifi-
cantly higher in no haptoglobin– compared with haptoglobin-receiving animals (P = 0.047) (Figure 2D). 
Haptoglobin therapy resulted in fewer increases in mean NTBI levels into the abnormal range during S. 
aureus pneumonia, independently of  exchange-transfusing RBCs.
Human haptoglobin binding stoichiometry to canine CFH. Ten samples with varying hemoglobin and hapto-
globin concentrations were suspended in canine plasma, and the percentage of  free hemoglobin that bound 
to haptoglobin was determined using the measured absorbance of  hemoglobin at 415 nm as a function of  
time and sedimentation distance. Figure 2E shows the absorbance vs. sedimentation distance for 3 study 
samples with different molar ratios of  hemoglobin to haptoglobin (68, 7.8, and 3.8) taken 15 minutes after 
the beginning of  sedimentation. The sample with 68-fold more hemoglobin than haptoglobin, as expected, 
sedimented similar to 100% free, unbound hemoglobin (Figure 2E). The other 2 samples sedimented more 
rapidly, consistent with a higher molecular weight and confirming that the canine hemoglobin binds to 
human haptoglobin. We found that, on average, there was 4.3 ± 1.4 hemoglobin molecules per haptoglo-
bin, consistent with the expectation that each haptoglobin α-β dimer binds 2 hemoglobin dimers (4 heme).
Human haptoglobin levels. In animals with S. aureus pneumonia randomized to receive haptoglobin 
therapy vs. septic controls (no haptoglobin), whether exchange-transfused or not, there were significant 
increases in mean human haptoglobin levels at all time points studied: 4–96 hours (Figure 3, A and B). 
The constancy of  the levels over these 96 hours suggests that we reached and maintained a steady state 
with our dosing regimen (2 doses of  100 mg/kg, doses given 3 hours apart, followed by 12.5 mg/kg/hour 
infusion until the 48-hour termination point). However, in animals with S. aureus pneumonia not transfused 
vs. transfused, mean haptoglobin levels were greater during the time of  (4–48 hours) exchange transfusion, 
and this reached statistical significance at 24 hours (i.e., mean haptoglobin levels in the treatment group 
at 24 hours vs. controls [no haptoglobin] levels were significantly increased more without vs. with trans-
fusion [interaction, P = 0.04]). In S. aureus pneumonia animals that were not exchange-transfused, greater 
mean haptoglobin level increases were associated with greater mean central venous pressure (CVP) levels 
and lower mean hematocrit levels at multiple time points. Mean CVP in the septic haptoglobin treatment 
group vs. septic controls (no haptoglobin) were significantly greater without vs. with exchange-transfusion 
at 13 and 48 hours (interaction), and mean hematocrit levels in the septic haptoglobin treatment group 
vs. septic controls (no haptoglobin) were significantly lower without vs. with exchange transfusion at 4 
and 10 hours (interaction; Figure 3, C–F). The S. aureus pneumonia animals without exchange transfu-
sion, thus, had higher mean haptoglobin levels, resulting in increased intravascular volume, increased CVP, 
and lower hemoglobin concentrations. The differential in haptoglobin levels and potential oncotic pressure 
effects cannot easily explain the similar beneficial effects seen with haptoglobin therapy in this study in 
septic animals with and without exchange transfusion, since animals with S. aureus pneumonia that were 
exchange-transfused had no significant differences in mean CVP with haptoglobin therapy compared with 
septic controls (no haptoglobin). There were also no significant differences in cardiac filling pressures as 
hemoglobin (in heme) to haptoglobin (in α-β dimer), essentially CFH, sedimented much more slowly than the others. The other 2 samples with much greater 
ratios of hemoglobin to haptoglobin sedimented more rapidly, consistent with a higher molecular weight and confirming that the canine hemoglobin binds 
to human haptoglobin. Analysis of the sedimentation data provided the percentage of fast (bound) and slow (unbound) sediment species. That percentage 
determination, together with the known total concentrations of haptoglobin and hemoglobin in each sample, was used to calculate the binding stoichiome-
try. For example, when 227 μM hemoglobin was mixed with 37 μM haptoglobin, 75% of the total hemoglobin (170.25 μM) was a slowly sedimenting species. 
Thus, 170.25/37 = 4.6 hemoglobin molecules (in heme) per haptoglobin (in α-β dimers). Comparisons of all variables (except survival) were made based on 
contrasts in linear mixed models, which allow us to account for repeated measurements of each animal and the actual pairing of animals within each cycle.
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measured by mean pulmonary artery occlusion pressure (PAOP) in animals with S. aureus pneumonia that 
were exchange-transfused and treated with haptoglobin compared with septic controls (no haptoglobin) 
over the first 48 hours (Figure 3G). However, there were significant increases in mean PAOP at 60 and 72 
hours compared with baseline in S. aureus animals that were exchange-transfused but only among septic 
controls (no haptoglobin) compared with haptoglobin-treated septic animals (Figure 3D). Finally, there 
were also no significant differences in mean PAOP pressures in S. aureus pneumonia animals that did not 
receive an exchange transfusion of  RBC between haptoglobin-treated animals vs. septic controls (no hapto-
globin) throughout the experiment (Figure 3H).
Metabolic function. Animals with S. aureus pneumonia that were exchange-transfused and randomized to 
receive haptoglobin therapy had significantly smaller decreases in mean arterial pH at 48 and 60 hours com-
pared with septic controls (Figure 4A). This apparent beneficial effect of  haptoglobin therapy on acid-base 
balance (i.e., pH) during sepsis with exchange transfusion was also associated with an overall improved 
metabolic profile as follows: During sepsis with exchange transfusion, haptoglobin therapy resulted in sig-
nificantly smaller increases in mean partial pressure of  CO2 (pCO2) at 48 and 60 hours compared with 
septic controls (Figure 4C), as well as significantly smaller decreases in base deficit at 60 hours (P = 0.008) 
(Figure 4E) and significantly lower mean serum lactate levels at 7, 13, 24 and 48 hours (Figure 4G).
Animals with S. aureus pneumonia that were exchange-transfused but not randomized to receive hap-
toglobin therapy had significantly smaller decreases in mean arterial pH at 36 and 60 hours compared with 
septic controls (Figure 4B). This beneficial effect of  haptoglobin therapy on pH was associated with an 
overall improved metabolic profile as follows: Septic controls had a significantly increased mean pCO2 at 
24 and 60 hours compared with baseline, whereas there were no significant increases in mean pCO2 from 
baseline at all time points studied in septic animals treated with haptoglobin (Figure 4D). Haptoglobin ther-
apy resulted in smaller increases of  the mean base deficit at all time points studied that reached statistical 
significance at 96 hours (P = 0.04) (Figure 4F). Lastly, in septic controls, there was a significant increase in 
serum mean lactate level at 13 and 36 hours compared with baseline, whereas among septic animals with 
haptoglobin therapy, no significant increases in mean lactate levels compared with baseline were found 
throughout (Figure 4H).
C-reactive protein, TNF-α, IL-6, and IL-10. Animals with S. aureus pneumonia randomized to receive hap-
toglobin therapy and septic controls had no significant changes from baseline at 4, 16, and 24 hours in mean 
TNF-α, IL-6, and IL-10 levels in either model studied. There were also no significant difference comparing 
the effect of  haptoglobin therapy vs. septic controls, except for in the sepsis-only model. The decrease from 
baseline in mean IL-10 levels with haptoglobin therapy at 4, 16, and 24 hours — although nonsignificant 
compared with baseline — was a significantly greater decrease compared with septic controls at all these 
time points (Supplemental Table 5). There were marked similar increases (pg/ml) from baseline in mean 
(SEM) C-reactive protein levels with haptoglobin therapy and in septic controls in both models at 24 hours 
(no transfusion: 18.6 ± 0.8 pg/ml at baseline and 19.3 ± 0.8 pg/ml at 24 hours; transfusion: 16.7 ± 0.9 at 
baseline and 17.5 ± 0.9 at 24 hours) and 48 hours (no transfusion; 19.1 ± 0.8 pg/ml and 19.6 ± 0.9 pg/
ml; and transfusion: 18.2 ± 0.9 pg/ml and 19.0 ± 0.9 pg/ml, respectively; all, P < 0.0001). However, these 
elevations were not significantly different between haptoglobin therapy and septic controls at 24 hours or 
48 hours in either model studied (P > 0.40). Thus, we found no evidence of  an antiinflammatory effect of  
haptoglobin therapy in this study during sepsis or sepsis with RBC transfusion. 
Renal, hepatic, and cardiac function; electrolytes; glucose; platelets; transferrin bound iron levels; and white blood 
cells. Animals with S. aureus pneumonia randomized to receive haptoglobin therapy vs. septic controls had 
some differences in mean values for renal (creatinine and blood urea nitrogen; BUN), hepatic (alanine 
aminotransferase; ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and total bili-
rubin (Supplemental Table 1) and cardiac function (cardiac output by thermodilution technique [V24/26, 
Philips Medical]) and left ventricular ejection fraction as measured by cardiac echocardiography (Sonos 
5500, Philips Medical) (Supplemental Table 2), electrolytes (sodium, potassium, and chloride), and glucose 
Figure 3. Human haptoglobin, central venous pressure, hematocrit, and pulmonary artery occlusion pressure measurements at serial time points. The 
format is similar to Figure 1, except that human haptoglobin, central venous pressure, hematocrit, and pulmonary artery occlusion pressure are measured 
over 96 hours after S. aureus challenge in canines receiving haptoglobin or no haptoglobin with (A, C, E, G) or without RBC exchange transfusion (B, D, F, H) 
Comparisons of all variables (except survival) were made based on contrasts in linear mixed models, which allow us to account for repeated measurements 
of each animal and the actual pairing of animals within each cycle.
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(Supplemental Table 3), as well as platelet counts and transferrin-bound iron levels (Supplemental Table 4) 
and circulating white blood cells (Supplemental Figure 3) from 4–96 hours in one sepsis model or the other. 
However, these mostly random time point differences in one model or the other cannot easily explain the 
consistent beneficial effects of  haptoglobin therapy in this study with and without RBC exchange transfu-
sion on shock, LIS, and survival.
Discussion
Over the last half-century, numerous agents tested in sepsis trials, enrolling tens of  thousands of  patients, 
have failed to show reproducible benefits (27–30). Most of  these failed therapeutic approaches were attempts 
to decrease inflammation during sepsis by inhibiting host responses to bacteria. Here, in randomized con-
trolled trials in our canine model of  lethal S. aureus pneumonia that was originally designed to study the 
effect of  haptoglobin administration on exchange transfusion, marked elevations were demonstrated in 
plasma CFH levels during sepsis, even in the absence of  blood transfusion. Haptoglobin therapy bound 
CFH and decreased CFH and iron levels associated with an improved metabolic profile (pH, lactate levels), 
less lung injury, decreased severity of  shock, and improved survival rates. We posit that haptoglobin binds 
increased levels of  CFH in sepsis, compartmentalizes these bound complexes to the intravascular space, 
and promotes CFH clearance, decreasing plasma iron — an essential nutrient for bacteria — and prevent-
ing extravascular oxidative injury from CFH and iron. As a result, haptoglobin appears to be an effective 
treatment and may offer a promising alternative strategy to treat sepsis because of  its ability to enhance 
natural host mechanisms (16), in contrast to previous approaches designed to inhibit them (30). Plasma-de-
rived human haptoglobin has been approved in Japan since 1985 for multiple clinical indications associated 
with elevated CFH levels, including hemolytic anemias, and for use during extracorporeal circulation (31).
Haptoglobin infusions were associated in both our sepsis models with earlier spikes in CFH levels, 
which is indirect evidence that haptoglobin successfully compartmentalized the bound complexes to the 
intravascular space. Using analytical centrifugation techniques, we confirmed human haptoglobin was 
binding canine CFH. The large haptoglobin-CFH complexes formed would be greatly confined to the 
intravascular space until metabolized through specific receptors by reticuloendothelial cells, unlike free 
CFH molecules, which dissociates into dimers that pass into the urine and extravasate into the extravas-
cular space. We measured CFH using an assay that measures free CFH in the plasma, as well as bound-
CFH. As haptoglobin binds CFH, the resultant complexes are confined to the intravascular circulation, 
decreasing the volume of  distribution of  CFH and causing an earlier spike in Drabkin’s-measured CFH 
levels compared with studies without haptoglobin. In septic canines with or without RBC exchange 
transfusion, haptoglobin produced earlier rises in CFH levels and accelerated CFH clearance, which 
resulted in free iron levels that were overall lower and within the normal ranges. This compartmental-
ization of  CFH has the added potential benefit during sepsis of  decreasing the ability for CFH and iron 
to cause extravascular oxidative tissue injury.
Studies in normal guinea pigs and mice have previously reported that haptoglobin therapy can ame-
liorate the direct nephrotoxic and lethal effects of  elevated CFH from stored blood (6, 8, 32). A study in 
mice found that administering hemopexin, another naturally occurring protein that binds heme released 
by CFH, prevented tissue damage and decreased mortality during cecal-ligation and puncture (CLP) (21). 
Other murine studies employing CLP to induce sepsis found that genetic disruption of  haptoglobin expres-
sion enhances mortality and administering haptoglobin concentrates improves mortality in WT and mice 
genetically deficient for haptoglobin (33).
In previous studies, we found that the combination of  transfusing RBCs stored for 6 weeks with 
increasing dose challenges of  S. aureus progressively worsened the dose-dependent effects of  septic 
shock (12). While the elevated levels of  CFH remained relatively stable across bacterial doses, the free 
iron levels progressively decreased in a dose-dependent fashion (12). This observation is consistent 
with the notion that, as the bacterial dose increased, S. aureus scavenged and utilized the iron released 
with hemolysis, which likely promoted bacterial growth and worsened septic shock. In healthy canines 
Figure 4. Arterial blood gas comparison over the 96-hour duration of the sepsis study. The format is similar to Figure 1, except that quantitative arterial 
blood gas measurements (pH, pCO2, base excess) and lactate levels are compared over 96 hours after S. aureus challenge in canines receiving haptoglobin 
or no haptoglobin with (A, C, E, G) or without RBC exchange-transfusion (B, D, F, H). Comparisons of all variables (except survival) were made based on con-
trasts in linear mixed models, which allow us to account for repeated measurements of each animal and the actual pairing of animals within each cycle.
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without infection, transfusing stored RBCs with elevated CFH levels is nontoxic (12), producing none 
of  the nephrotoxic or lethal effects seen in healthy guinea pigs and mice (6, 8, 32). In hemorrhag-
ic shock models in canines without infection, resuscitation with stored RBCs with high CFH levels 
improved the hemodynamic response to hemorrhage reperfusion (34). These findings lead us to con-
clude that iron from CFH is a relevant if  not critical factor during bacterial infection and can explain, 
in large part, why elevation in CFH worsens the condition of  septic canines and why increases in CFH 
are associated with increased mortality in humans, especially those at risk for or with an established 
infection (3–5). Haptoglobin infusion, by binding and increasing clearance of  CFH, could promote 
nutritional immunity by isolating the iron from bacteria, inhibiting bacterial growth, and curbing the 
effects of  bacterial infections. Haptoglobin compartmentalizing CFH to the intravascular spaces may 
also reduce tissue injury by excluding CFH from extravascular sites of  NO production and from NO 
effector sites, preventing NO depletion and ischemic injury (35, 36). In addition, binding the heme 
molecule in CFH could also reduce proinflammatory injury in the lung (15, 16, 22) and direct oxida-
tive lung injury (16, 17). Haptoglobin could also directly bind proinflammatory mediators and improve 
outcomes (33). However, we found no evidence that haptoglobin infusions directly affect proinflam-
matory mediators such as C-reactive protein, which are released during sepsis.
The beneficial effects of  haptoglobin therapy in our sepsis studies without RBC transfusion were 
biochemically and physiologically less evident compared with sepsis with transfusion, and the survival 
benefit was smaller (33% vs. 43% relative decrease in mortality), despite studying more animals (n = 
24 vs. n = 18). Conversely, the haptoglobin effect on lung injury was greater without RBC transfusion, 
with statistically significant differences at many more time points (10, 24, 36, 48, 60, and 72 hours vs. 
36, 48, and 60 hours). This apparently contradictory observation may reflect the presence of  2 separate 
haptoglobin effects on survival, one dependent on CFH clearance and the second independent of  CFH 
but related to interspecies anaphylaxis. During our pretrial dose-finding studies, we found that human 
haptoglobin can induce anaphylaxis in canines in a dose-dependent fashion (Supplemental Methods). 
The higher haptoglobin levels at earlier time points in the sepsis without exchange-transfusion ani-
mals, due to the absence of  the wash out that occurs with exchange transfusion, may have triggered 
immune activation sufficient to worsen the survival outcome of  the bacterial infection. Cross species 
anaphylaxis would not be an issue for clinical trials. Human serum albumin can also bind heme, albeit 
weakly (32, 37). Albumin binding may have reduced the relative beneficial survival effect of  haptoglo-
bin binding of  CFH. Using PBS instead of  albumin as a control solution during the RBC exchange 
transfusion trial avoided this possibility, but it does not easily explain the contradictory effect on lung 
injury (32, 37).
In our animal model, a sudden bolus of  bacteria is given to an otherwise healthy animal. Human 
bacterial infection likely begins with a small nidus of  infection and progresses slowly over time, often due 
to some impairment in host defenses. These differences may make our experimental model results less 
applicable to the human condition. Furthermore, our results could vary with a different bacterial species, 
dose challenge, site of  infection, or experimental species. Lastly, the model cannot fully reproduce all the 
treatments and heterogeneity in human infections, which could make the beneficial effects seen here non-
reproducible in humans.
In conclusion, our studies demonstrate that haptoglobin binds CFH, compartmentalizes the mol-
ecule into the intravascular space, quickly clears it from the circulation, and decreases the amount of  
available intravascular iron. Bacteria that cause human infections are known to produce hemolysins, a 
virulence factor that disrupts RBCs and releases CFH into the circulation (38, 39). Elevated levels of  
CFH have been described with clinical sepsis, and higher levels have been correlated with increased 
mortality (3–5). We found that binding and clearing of  CFH during bacterial infection was associ-
ated with an improved metabolic profile (pH, lactate levels), decreases in shock score, and lung inju-
ry — all findings consistent with and supporting our demonstrated improvement in sepsis mortality 
rates. Our haptoglobin hypothesis has a theoretically better risk-benefit profile than previous therapeu-
tic approaches inhibiting inflammation tested for bacterial sepsis due to the ability of  haptoglobin to 
enhance a normal host defense mechanism (16), rather than inhibiting it (30). These findings support 
a role for pharmacologic infusions of  haptoglobin as a biologically plausible new approach to bacterial 
sepsis for testing in human sepsis trials.
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Methods
Supplemental Methods are available online with this article.
In the first of  2 sepsis experiments, 24 purpose-bred beagles (18–30 months old, 9–2.5 kg, Covance 
Inc.) with S. aureus pneumonia were randomized to receive i.v. human haptoglobin (2-1 and 2-2) plas-
ma fraction concentrates (a gift from CSL Bearing) (800 mg/kg total dose, in 2 divided 100 mg/kg 
bolus doses at 4 and 7 hours after infection followed immediately by a 600 mg/kg continuous infusion 
over 48 hours) or an osmotically equivalent volume of  human 25% albumin (Talecris Biotherapeutics; 
Supplemental Figure 4). This model has been shown to reproduce the cardiovascular abnormalities 
of  human septic shock (40). To create conditions translatable to the clinical intensive care unit envi-
ronment, all animals received fluids, vasopressors, mechanical ventilation, and sedation titrated to 
physiologic endpoints, as well as oxacillin (Auromedics LLC) 30 mg/kg every 4 hours starting 4 hours 
after bacterial challenge for 96 hours (11, 41). All animals were treated identically, except for the 
experimental intervention, and — if  alive after 96 hours — were considered survivors and euthanized.
In a second sepsis experiment, 18 purpose-bred beagles (18–30 months old, 9–12.5 kg) with experi-
mental S. aureus pneumonia were additionally exchanged-transfused with 80 ml/kg of  7-day-old stored 
canine universal donor blood (DEA 1.1 ABRINT) in 4 divided doses (20 ml/kg) given sequentially 
every 3 hours starting 4 hours after infection but otherwise treated the same and given haptoglobin 
therapy as above (Supplemental Figure 1). Albumin was not used in the second experiment as a control 
solution to avoid binding heme, which is expected to increase after hemolysis of  transfused RBCs (32, 
37). The PBS cohort in the second experiment serves as a vehicle control. A detailed description of  the 
experimental model and procedures has been published previously (11, 41). See Supplemental Meth-
ods for details of  haptoglobin administration, desensitization protocol, and binding studies, as well as 
details of  other laboratory procedures performed and the statistical methods.
Statistics. Survival times were plotted using Kaplan-Meier survival curves and analyzed using strati-
fied log-rank tests and stratified Cox proportional hazards models. For all other variables, changes from 
baseline values were analyzed. To evaluate shock reversal, we standardized the mean arterial pressure 
(MAP) and norepinephrine (NE) concentration using Z-scores and then calculated a shock reversal 
score based on the difference of  their respective Z scores (higher score indicates improvement in shock 
reversal). To evaluate pulmonary function, we constructed a LIS (lower score indicates less lung injury) 
based on the first principal component of  mean pulmonary artery pressure, arterial alveolar oxygen gra-
dient, plateau pressures, breathing rates, and a pulse oximeter oxygen saturation measurement (SpO2). 
Linear mixed models were used to account for repeated measurements of  each animal and the actual 
pairing of  animals within each cycle. SAS version 9.3 was used for all analyses. All p-values are 2-tailed 
and considered significant if  p ≤ 0.05.
Study approval. All experiments were conducted after protocol approval (no. CCM13-14) by the Animal 
Care and Use Committee of  the Clinical Center at the NIH.
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